Inflammation provoked by Mycoplasma pneumoniae extract: Implications for combination treatment with clarithromycin and dexamethasone

FEMS Immunology and Medical Microbiology

Volumn 62, Issue 2, 2011, Pages 182-189

  Hirao, Susumu ^a   Wada, Hiroo ^a   Nakagaki, Kazuhide ^b   Saraya, Takeshi ^a   Kurai, Daisuke ^a   Mikura, Shinichiro ^a   Yasutake, Tetsuo ^a   Higaki, Manabu ^a   Yokoyama, Takuma ^a   Ishii, Haruyuki ^a   Nakata, Koh ^c   Aakashi, Toshi ^d   Kamiya, Shigeru ^a   Goto, Hajime ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^d TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Clarithromycin; Dexamethasone; Immunomodulation; Macrolide; Mycoplasma pneumoniae

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CLARITHROMYCIN; CYTOKINE; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RANTES; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; INFLAMMATION; MOUSE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CLARITHROMYCIN; CYTOKINES; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA;

EID: 79958831482     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00799.x     Document Type: Article

References (40)

1. Abe S, Nakamura H, Inoue S, Takeda H, Saito H, Kato S, Mukaida N, Matsushima K & Tomoike H (2000) Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Resp Cell Mol Biol 22: 51-60.
2. Bailly S, Pocidalo JJ, Fay M & Gougerot-Pocidalo MA (1991) Differential modulation of cytokine production by macrolides: interleukin-6 production is increased by spiramycin and erythromycin. Antimicrob Agents Ch 35: 2016-2019.
3. Barnes PJ & Adcock IM (1997) NF-kappa B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 18: 46-50.
4. Chmura K, Bai X, Nakamura M, Kandasamy P, McGibney M, Kuronuma K, Mitsuzawa H, Voelker DR & Chan ED (2008) Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells. Am J Physiol Lung C 295: L220-L230.
5. Chu HW, Honour JM, Rawlinson CA, Harbeck RJ & Martin RJ (2003) Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect Immun 71: 1520-1526.
6. Committee for t he Japanese Respiratory Society guidelines for the management of respiratory infections (2006) Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology 11 (suppl 3): S79-S133.
7. Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K & Takizawa H (2004) Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Ch 48: 1581-1585.
8. Garamori G, Oates T, Nicholson AG, Casolari P, Ito K, Barnes PJ, Papi A, Adcock IM & Chung KF (2009) Activation of NF-kappaB transcription factor in asthma death. Histopathology 54: 507-509.
9. Hallamaa KM, Browning GF & Tang SL (2006) Lipoprotein multigene families in Mycoplasma pneumoniae. J Bacteriol 188: 5393-5399.
10. Hardy RD, Rios AM, Chavez-Bueno S, Jafri HS, Hatfield J, Rogers BB, McCracken GH & Ramilo O (2003) Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Ch 47: 1614-1620.
11. Hart LA, Krishnan VL, Adcock IM, Barnes PJ & Chung KF (1998) Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Resp Crit Care 158: 1585-1592.
12. Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M & Hoiby N (2007) Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates P. aeruginosa lung infection in Cftr -/- mice. Antimicrob Agents Ch 51: 3677-3687.
13. Ikeda K, Wu D & Takasaka T (1995) Inhibition of acetylcholine-evoked Cl- currents by 14-membered macrolide antibiotics in isolated acinar cells of the guinea pig nasal gland. Am J Resp Cell Mol 13: 449-454.
14. Kaneko Y, Yanagihara K, Seki M, Kuroki M, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Kadota J & Kohno S (2003) Clarithromycin inhibits over production of muc5ac core protein in murin model of diffuse panbronchiolitis. Am J Physiol Lung C 285: L847-L853.
15. Kannan TR & Baseman JB (2006) ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. P Natl Acad Sci USA 103: 6724-6729.
16. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, Tokue Y, Watanabe A & Nukiwa T (2002) Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemoth 49: 745-755.
17. Koh YY, Park Y, Lee HJ & Kim CK (2001) Levels of interleukin-2, interferon-γ, and interleukin-4 in bronchoalveolar lavage fluid from patients with Mycoplasma pneumonia: implication of tendency toward increased immunoglobulin E production. Pediatrics 107: E39.
18. Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M & Ito K (1999) Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Ch 43: 907-911.
19. Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion BP, Gaydos CA & Martin RJ (1998) Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Resp Crit Care 158: 998-1001.
20. Kudoh S, Azuma A, Yamamoto M, Izumi T & Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Resp Crit Care 157: 1829-1932.
21. Mandell LA, Wunderink RG, Anzueto A et al. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44: S27-S72.
22. Morikawa K, Watabe H, Araake M & Morikawa S (1996) Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Ch 40: 1366-1370.
23. Nisar N, Guleria R, Kumar S, Chand Chawla T & Ranjan Biswas N (2007) Mycoplasma pneumoniae and its role in asthma. Postgrad Med J 83: 100-104.
24. Pradervand S, Maurya MR & Subramaniam S (2006) Identification of signaling components required for the prediction of cytokine release in RAW 264.7 macrophages. Genome Biol 7: R11.
25. Saraya T, Wada H, Kurai D et al. (2007) Involvement of lymophcytes in the murine model of Mycoplasma pneumoniae pneumonia. Am J Resp Crit Care 175: A674 (abstract presented in ATS 2007 at San Francisco).
26. Sato Y, Kaneko K & Inoue M (2007) Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production. Prostag Leukotr Ess 76: 181-188.
27. Schultz MJ (2004) Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemoth 54: 21-28.
28. Sekine H, Taguchi H, Watanabe H, Kawai S, Fujioka Y, Goto H, Kobayashi H & Kamiya S (2009) Immunological analysis and pathological examination of gnotobiotic mice monoassociated with Mycoplasma pneumoniae. J Med Microbiol 58: 697-705.
29. Shimizu T, Kida Y & Kuwano K (2005) A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-κB through TLR1, TLR2, and TLR6. J Immunol 175: 4641-4646.
30. Shinkai M, Foster GH & Rubin BK (2006) Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung C 290: L75-L85.
31. Sofer D, Gilboa-Garber N, Belz A & Garber NC (1999) 'Subinihibitory' erythromycin represses production of Pseudomonas aeruginosa lectins, autoinduces and virulence factors. Chemotherapy 45: 335-341.
32. Sohn MH, Lee KE, Choi SY, Kwon BC, Chang MW & Kim KE (2005) Effect of Mycoplasma pneumoniae lysate on interleukin-8 gene expression in human respiratory epithelial cells. Chest 128: 322-326.
33. Sutherland ER & Martin RJ (2007) Asthma and atypical bacterial infection. Chest 132: 1962-1966.
34. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y & Sasaki T (2006) Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Ch 50: 709-712.
35. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, Gomez AM, Esposito S, Principi N & Hardy RD (2008) The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 198: 1180-1188.
36. Tanaka H, Koba H, Honma S, Sugaya F & Abe S (1996) Relationships between radiological pattern and cell-mediated immune response in Mycoplasma pneumoniae pneumonia. Eur Respir J 9: 669-672.
37. Waites KB & Talkington DF (2004) Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17: 697-728.
38. Yamasaki T, Ichimiya T, Hirai K, Hiramatsu K & Nasu M (1997) Effect of antimicrobial agents on the piliation of Psedudomonas aeruginosa and adherence to mouse tracheal epithelium. J Chemother 9: 32-37.
39. Yanagihara K, Tomono K, Imamura Y et al. (2002) Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murin model. J Antimicrob Chemoth 49: 867-870.
40. Yasutomi M, Ohshima Y, Omata N, Yamada A, Iwasaki H, Urasaki Y & Mayumi M (2005) Erythromycin differentially inhibits lipopolysaccharide- or poly(I:C)-induced but not peptidoglycan-induced activation of human monocyte-derived dendritic cells. J Immunol 175: 8069-8076.